These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16417813)

  • 1. Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?
    Hurwitz B
    Int MS J; 2005 Aug; 12(2):39-41. PubMed ID: 16417813
    [No Abstract]   [Full Text] [Related]  

  • 2. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies--an update.
    Donoghue S; Greenlees C
    Expert Opin Investig Drugs; 2000 Jan; 9(1):167-71. PubMed ID: 11060669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple lessons for multiple sclerosis.
    Hauser SL
    N Engl J Med; 2008 Oct; 359(17):1838-41. PubMed ID: 18946071
    [No Abstract]   [Full Text] [Related]  

  • 5. Investigational drug therapies of treatment of multiple sclerosis.
    Panitch HS
    Mult Scler; 1996 Sep; 2(2):66-77. PubMed ID: 9345383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Tysabri survived.
    Huggett B
    Nat Biotechnol; 2009 Nov; 27(11):986. PubMed ID: 19898447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R
    Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
    [No Abstract]   [Full Text] [Related]  

  • 8. [Biological treatment of multiple sclerosis].
    Sørensen PS; Sellebjerg F
    Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options.
    Bermel RA; Cohen JA
    Lancet Neurol; 2011 Jan; 10(1):4-5. PubMed ID: 21163434
    [No Abstract]   [Full Text] [Related]  

  • 10. Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland.
    Bailey B
    Ir J Med Sci; 2011 Jun; 180(2):337-41. PubMed ID: 21293948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
    Rice G
    Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
    [No Abstract]   [Full Text] [Related]  

  • 12. Issues in pharmaceutical lotteries: the case of interferon beta-1b.
    Manocchia M; Lasagna L
    Clin Pharmacol Ther; 1997 Sep; 62(3):241-7. PubMed ID: 9333099
    [No Abstract]   [Full Text] [Related]  

  • 13. Rebif offers another option for treating multiple sclerosis.
    Ryan M
    J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
    [No Abstract]   [Full Text] [Related]  

  • 14. Nursing management of MS patients receiving interferon beta-1b therapy.
    Costello K; Conway K
    Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 16. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Kappos L
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424020
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
    Curtiss FR
    J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid onset of ulcerative colitis after treatment with interferon β1a in a patient with multiple sclerosis.
    Tuna Y; Başar O; Dikici H; Köklü S
    J Crohns Colitis; 2011 Feb; 5(1):75-6. PubMed ID: 21272812
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravenous immunoglobulin and multiple sclerosis.
    Achiron A; Miron S
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):247-54. PubMed ID: 16391400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta 1a.
    Pozzilli C; Koudriavtseva T
    Baillieres Clin Neurol; 1997 Oct; 6(3):481-93. PubMed ID: 10101585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.